By Rachel Minnick
CISCRP’s many educational programs and initiatives are fueled by the dedication and involvement of our supporters and volunteers. We are pleased to be spotlighting two of these supporters in this edition of the newsletter, both of whom made important contributions to our recent USA Today supplement on Clinical Trials. The supplement is part of our National Clinical Trial Outreach and Awareness Initiative and we caught up with 2 of our top sponsors – Biogen and TransCelerate Biopharma Inc. – to find out what drives their company’s passion for clinical research education and awareness. We asked each one to comment on their company’s commitment to raising public awareness about clinical research and how this fits into their organization’s overall mission. We also asked what other specific initiatives – in addition to supporting CISCRP’s National Outreach Campaign – that their companies are working on at this time to raise awareness about clinical research.
Biogen develops medicines for debilitating medical conditions with the goal of making a meaningful difference in patients’ lives. Patients are at the center of everything we do here at Biogen. Clinical research is a critical part of getting meaningful therapies to patients around the world, so it is important we partner with CISCRP and other companies to raise awareness of opportunities to participate in clinical research. We truly appreciate and thank clinical research participants and their families for their enormous contribution in helping to advance medical research and discover potential new treatments.
In addition to supporting CISCRP’s National Outreach Campaign, Biogen has developed educational tools as part of our commitment to raising awareness of clinical research and making information more accessible. Biogen has created videos, booklets and clinical research study websites that explain what clinical research is and what participation means for patients and families. Furthermore, in order to help inform and educate patients about the clinical trials in which they participate, Biogen is committed to provide a factual summary of clinical trial results in plain language and make the summaries available to research participants at the end of the study. Biogen continues to seek partnerships and novel ways in which we can meaningfully engage the public on the topic of clinical research and provide helpful information to patients and families.
One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS), has the first and only approved treatment for spinal muscular atrophy (SMA) and is at the forefront of research into new medicines for neurological and neurodegenerative conditions. Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options. For more information, visit www.biogen.com.
TransCelerate Biopharma Inc.
As an industry, we have an opportunity to improve the links between clinical research, the public (patients, and their care-givers), and health care delivery (point of care/HCPs). Today, the role and potential impact of clinical research is not broadly known, and misconceptions and mistrust surrounding clinical research persist. There is low engagement with clinical research, low consideration of clinical trials as a care option, and an overall disconnect between available clinical trials and potential participants. Individual pharmaceutical companies are making investments to engage with communities, attempting to build awareness, and developing recruitment campaigns for clinical trials. We believe we can have much bigger impact by pooling our efforts together to influence sentiment and understanding of clinical trials more broadly. This can have a substantial ripple effect on the clinical research enterprise.
Our mission is “to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines.” Critical to the development of innovative new therapies, are trial participant volunteers, and a shared understanding in the public of the value medicine research and development brings to our society.
We envision a future in which key stakeholders are better informed about clinical research, and recognize it as a critical component of advancing population health. A future where there is increased discussion of clinical trial options between HCPs and their patients, and information about clinical trial options is available in clear and straightforward language. We want to inspire and equip healthcare professionals to engage in more frequent and more fulfilling conversations with patients about clinical research and clinical trial options.
TransCelerate BioPharma Inc. was launched in 2012 as a non-profit organization to improve the health of people around the world by simplifying and accelerating the research and development of innovative new therapies. For more information, visit www.transceleratebiopharmainc.com.
We want to thank Biogen and TransCelerate for their dedication to CISCRP’s mission and for helping to create awareness about the importance of clinical research. Be sure to check out the USA Today supplement on Clinical Trials HERE!
We will spotlight a different supporter or volunteer in each Newsletter, so stay tuned for new features each quarter.